CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
1
BRINGING UNTAPPED
MEDTECH DISCOVERIES
TO
MARKET
Executive
summary
June 2013
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
QUATTROCENTO'S CAPITAL
RAISING OF 15 M€
Quattrocento is looking to develop its capacity
to build and create innovative medtech
companies with new shareholders who wish
to bring their know-how and networks of
relationships to the process.
OBJECTIVE
Created in 2010 by experienced
entrepreneurs in the medtech sector,
Quattrocento transforms untapped
discoveries of the leading public research
labs in Paris into innovative medical
technology products with strong commercial
value, with a particular focus on measurement
instruments for biotech research and
diagnostic devices.
USE OF FUNDS
Create and build around ten subsidiaries in
the next 5 years, of which at least 1 or 2 will
achieve a substantial market presence and
achieve a stock exchange listing
•
Create and launch new subsidiaries: 4 over
the next 24 months
•
Finance the development of the 4 existing
subsidiaries alongside new investors
(external investors)
•
Reinforce the operational team with a
technology/market analyst and a financial
controller
2
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
QUATTROCENTO, INDUSTRIALIST IN EARLYSTAGE
DEVELOPMENT
OFhave
MEDTECH
COMPANIES
Paris-based Quattrocento’s founders
• Creation and development of
assembled the resources and expertise to
“industrialise” the seed stage of start-ups
such that overcomes the obstacles to getting
innovative products to market, more quickly
and more cheaply:
businesses in close collaboration with
researchers wishing to remain in their
research labs
•
End-to-end process of execution and
financing – Early evaluation of commercial
potential; protection of intellectual property,
development of an economic demonstrator,
creation, as a subsidiary of Quattrocentro,
of the company which will commercialise
the product
•
Highly experienced team with all the skills
and experience necessary to bring each
project to fruition : science, marketing,
development, strategy, intellectual property
3
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
A POWERFUL COMBINATION
OF OPTIMAL ECOSYSTEM AND RESOURCES
Excellent sourcing giving early access to
research projects
•
•
Based in the Latin Quarter of Paris, in close
proximity to the leading research
establishments, the Quattrocento team has
close links with researchers, built over 15
years of collaboration
Good relationships with the technology
transfer offices, which facilitates the
development of the intellectual property of
Quattrocento companies
Experienced entrepreneurial team
•
Highly complementary founding team
members, with a blend of scientific,
industrial and entrepreneurial expertise,
having already collaborated on a medtech
startup, sold in 2011 at an attractive price
•
A committee of shareholder-experts, which
advises on projects, and to whose
members Quattrocento can outsource
project requirements
Efficient use of resources
•
Pooling of expertise across Quattrocento’s
subsidiaries
•
Financing of subsidiaries that closely
follows the intensity of each phase of
development
Active management of the portfolio of
subsidiaries, with the flexibility to arbitrate
between the continued development or sale of
subsidiaries at every stage of the process
4
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
AN INDUSTRIAL PROJECT
WITH INDUSTRIAL REVENUES
Quattrocento is structured as an industrial
holding company with equity of 1.3M€
…and its return on investment from the
sale of portfolio companies
It derives its revenues from
Quattrocento will propose, on the occasion of
each exit, to distribute a part of the resulting
capital gain to it shareholders
•
Management fees from subsidiaries in the
early stages of development
•
Dividends from profitable subsidiaries
Investment in the subsidiaries will be made
only via the holding company.
5
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
6
RAPID RESULTS
4
subsidiaries
created
of which one is
already profitable in
2 years
Some examples
SUBSIDIARY 1
An innovative electrochemical system for
detecting biological molecules (DNA, RNA,
proteins), in advanced discussions with a
major international distributor
SUBSIDIARY 2
Microfluidic systems for cell tests (pharma
screening, toxicology), prototyped and ready
for industrialisation
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
QUATTROCENTO IDENTIFIES OPPORTUNITIES
IN THE UNEXPLOITED NUGGETS OF FRENCH
RESEARCH…
France has world class research but too few
results of this research are transformed into
innovative products due to two major
obstacles specific to the country:
•
Complexity of the process of technology
transfer (patent filing and negotiation of
patent licenses) in the multi-layered system
of French research and innovation
•
Lack of entrepreneurs with combined
competencies in science, industry and
business
A particularly acute problem in the medical
technology sector (“medtech”), despite the
opportunities that a global market of US$200
billion with sustained growth present.
7
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
… TO CREATE VALUABLE PRODUCTS FOR THE
MEDTECH MARKET,
A MARKET EXPERIENCING STRONG GROWTH AT
THE INNOVATIVE END
8
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
EXECUTIVE TEAM BEHIND QUATTROCENTO
BERTRAND FOURQUET - President
Prior to founding Quattrocento, he founded and managed Echosens, which develops innovative
cirrhosis diagnostic equipment. Created in 2001, Echosens was sold 10 years later at an
attractive price. Bertrand had previously gained business development experience creating and
developing the Spanish subsidiaries of well known consumer brands. He began his career in
mergers and acquisitions at Lazard Brothers and JP Morgan after graduating from ESSEC, one of
France’s leading business schools
LUC TALINI - Chief Executive Officer
A founder of Quattrocento, Luc was previously CTO of Echosens. He has held a number of senior
positions in leading research institutions. He worked for the technology transfer office of Paris
Diderot university after leading the CEDIB project (creation of a centre for innovation in
bioengineering).
He had his first entrepreneurial experience with Genescore, which he created following his post at
ESPCI in the neurobiology laboratory. Luc is an engineer and holds a doctorate in physics.
DAVID POIZAT - Technology And Quality Director
He joined Echosens in 2003 as head of industrialisation and production of the Fibroscan
medical system and quickly took over management of the company’s CE marking
and Quality systems (obtaining ISO 13485 in 2005), finally directing the after-sales department.
David is an Engineer in physics.
9
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
QUATTROCENTO’S ADVISORY COMMITTEE
12
experts, all
shareholders, advise
on the projects as a
committee and can
also individually
provide professional
services to portfolio
companies.
These experts have over 220 years of
combined experience:
Technical consulting; 3 PhDs: in Chemistry,
Physics and Biomedicine; an expert in
industrial computing; an expert in
industrialisation and quality in the biomedical
sector; a specialist in communication and
design, a human resources expert, specialists
in finance and marketing in the
innovation/start-up sector, specialists from
non-medical sectors able to bring cross-sector
knowledge and contacts, a specialist in
fundraising and a market researcher in the
medical sector.
10
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
11
THE FIRST SUBSIDIARIES
Elice l Alvéole l Thamis l Azalée
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
12
ESTABLISHED: October 2009
ORIGINATING LABORATORY: Laboratory of
Molecular Electrochemistry, Université Paris-Diderot
RESEARCH TEAM: Damien Marchal (Lecturer),
Benoît Limoges (Head of Laboratory)
INTELLECTUAL PROPERTY: 3 patents
WEBSITE: elice.fr
Technology
DETSCAN™ is a new technology for the electrochemical detection
of biological molecules (DNA, RNA, proteins). It offers the
advantages of technology from the electronics industry: robustness,
the option of miniaturisation, and low production costs.
Field of application/market
Elice will develop a robust, multi-purpose and easy-to-use DNA
detection device for routine use by researchers and technicians in
public and private research laboratories, and for molecular
diagnostics.
State of progress
In the launch phase, 1 demonstrator has been developed and a
Chief Operating Officer recruited. Elice currently requires €3M to put
its first product into production and bring it to market in 2014.
Aims
Financially stable company by 2015, 2017 turnover = €9M
Prizes/accolades
• Innovation prize from Diderot Valorisation 2006
• Winner of the National Competition for Aid in the Creation of
Innovative Technology Companies (2009 and 2010)
• Member of the Paris Biotech Santé incubator (2009)
• Scientipôle Initiative (2010)
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
13
ESTABLISHED: December 2010
ORIGINATING LABORATORIES: Department of
Physics and Biology at the École Normale Supérieure
(CNRS, ENS), Institut des Neurosciences de
Bordeaux (CNRS UMR5297)
RESEARCH TEAM: Maxime Dahan (Head of
Research at CNRS), Vincent Studer (CNRS
Researcher), Jean-Christophe Galas (CNRS
Researcher)
INTELLECTUAL PROPERTY: 4 patents
Technology
“Microsticker” is a technology enabling the development of
microfluidic devices with the following features:
• the ability to generate controlled gradients of chemical species on
top of culture cells;
• cells are cultivated on conventional media (Petri dish,
microplates) and under conventional conditions;
• the cells are not disturbed by the hydrodynamic flow.
Fields of application/market
Tests on live cells for:
• toxicology;
• stem cells and regenerative medicine;
• neurobiology and the search for molecules which are effective
against neurodegenerative diseases.
State of progress
In the seeding phase, development of a demonstrator is in progress
under the framework of an R&D contract with the Foundation de
Pierre-Gilles de Gennes. A market positioning analysis is also in
progress. The aim is to bring a first product to market in 2014.
Prizes/accolades
• Member of the Paris Biotech Santé incubator (2011)
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
14
ESTABLISHED: September 2011
ORIGINATING LABORATORIES: Prince-Ringuet
Laboratory, Polytechnique/IN2P3/CNRS
RESEARCH TEAM:
Maurice Haguenauer (Head of Research at
CNRS/CERN),
Patrick Poilleux (CNRS Technician)
INTELLECTUAL PROPERTY: 1 patent
Technology
Thamis’ technology is a patented method for measuring particle flow,
based on the use of a matrix of scintillating plastic fibres connected
to a digital camera. Thamis’ hodoscopes make it possible to
measure beam profile and intensity. They have a very good dynamic
range, are easy to use and require very little maintenance.
Field of application/market
Quality control of the particle beams used in hadrontherapy.
Hadrontherapy is a cancer treatment using a beam of particles
(protons, carbon ions) to destroy X-ray-resistant and inoperable
cancer cells. This highly effective method will have taken nearly 50
years to get off the ground on account of its infrastructure
requirements which are both large (particle accelerator) and
expensive (€100-150M). Since 2000, centres have been developing
regularly across the globe. It is deemed that one centre can serve 10
million habitants; currently, in France, there are 2 centres (Orsay,
Nice) in operation and 3 projects (Lyon, Caen and Toulouse).
State of progress
At an advanced stage of the launch phase, Thamis is in the process
of producing a series of hodoscopes for MedAustron, an Austrian
centre which is under construction.
Thamis aims to secure 1 order per year over the next 5 years.
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
15
ESTABLISHED: Summer 2012
ORIGINATING LABORATORY: Parametric Imaging
Laboratory, Université Pierre-et-Marie-Curie, CNRS
(UMR 7623)
RESEARCH TEAM: Pascal Laugier (Head of
Laboratory),
Jean-Gabriel Minonzio (CNRS Researcher),
Maryline Talmant (CNRS Researcher),
Emmanuel Bossy (Lecturer at ESPCI)
INTELLECTUAL PROPERTY: 2 patents
Technology
Azalée’s patented technology is based on the use of ultrasound to
probe cortical bone and obtain structural and mechanical
parameters.
Field of application/market
Medical devices to monitor the quality of cortical bone. A first
application is currently under development to assess the fragility of
the cortical bone in the context of osteoporosis, which affects
approximately 200 million people across the globe, 40 % of whom
are women over 50 years of age (and 20 % men). The fight against
osteoporosis, on a constant rise due to the ageing of the population,
is deemed in developed countries to be a major public health issue.
State of progress
Nearing completion of the assessment phase, a first demonstrator is
being used in the laboratory to conduct ex-vivo tests on bones. The
aim is to develop a demonstrator intended for a clinical pilot trial
scheduled to start at the Cochin Department of Rheumatology in
2013, with a view to being brought to market in 2015.
CONFIDENTIAL
QUATTROCENTO EXECUTIVE
SUMMARY JUNE 2013
16
SAS au capital de 1.371.024
euros
68, Bd de Port-Royal 75005 Paris
R.C.S. 522 012 939
lequattrocento.com